Literature DB >> 32940318

Pentacyclic triterpenoid acids in Styrax as potent and highly specific inhibitors against human carboxylesterase 1A.

Lu Wang1, Xiao-Qing Guan2, Rong-Jing He2, Wei-Wei Qin3, Yuan Xiong4, Feng Zhang2, Yun-Qing Song2, Peng-Chao Huo2, Pei-Fang Song2, Hui Tang4, Guang-Bo Ge2.   

Abstract

Human carboxylesterase 1A1 (hCES1A) is a promising target for the treatment of hyperlipidemia and obesity-associated metabolic diseases. To date, the highly specific and efficacious hCES1A inhibitors are rarely reported. This study aims to find potent and highly specific hCES1A inhibitors from herbs, and to investigate their inhibitory mechanisms. Following large-scale screening of herbal products, Styrax was found to have the most potent hCES1A inhibition activity. After that, a practical bioactivity-guided fractionation coupling with a chemical profiling strategy was used to identify the fractions from Styrax with strong hCES1A inhibition activity and the major constituents in these bioactive fractions were characterized by LC-TOF-MS/MS. The results demonstrated that seven pentacyclic triterpenoid acids (PTAs) in two bioactive fractions from Styrax potently inhibit hCES1A, with IC50 values ranging from 41 nM to 478 nM. Among all the identified PTAs, epibetulinic acid showed the most potent inhibition activity and excellent specificity towards hCES1A. Both inhibition kinetic analyses and in silico analysis suggested that epibetulinic acid potently inhibited hCES1A in a mixed inhibition manner. Collectively, our findings demonstrate that some PTAs in Styrax are potent and highly specific inhibitors of hCES1A and these constituents can be used as promising lead compounds for the development of more efficacious hCES1A inhibitors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32940318     DOI: 10.1039/d0fo01732a

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  5 in total

Review 1.  Storax, A Promising Botanical Medicine for Treating Cardio-Cerebrovascular Diseases: A Review.

Authors:  Zhuo Xu; Danni Lu; Jianmei Yuan; Mihong Ren; Rong Ma; Qian Xie; Yong Li; Jinxiu Li; Jian Wang
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

2.  Storax Inhibits Caveolae-Mediated Transcytosis at Blood-Brain Barrier After Ischemic Stroke in Rats.

Authors:  Min Zhou; Dongna Li; Qian Shen; Lei Gao; Pengwei Zhuang; Yanjun Zhang; Hong Guo
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

3.  Discovery of human pancreatic lipase inhibitors from root of Rhodiola crenulata via integrating bioactivity-guided fractionation, chemical profiling and biochemical assay.

Authors:  Li-Juan Ma; Xu-Dong Hou; Xiao-Ya Qin; Rong-Jing He; Hao-Nan Yu; Qing Hu; Xiao-Qing Guan; Shou-Ning Jia; Jie Hou; Tao Lei; Guang-Bo Ge
Journal:  J Pharm Anal       Date:  2022-04-08

Review 4.  A Review on Obesity Management through Natural Compounds and a Green Nanomedicine-Based Approach.

Authors:  Monika Bhardwaj; Poonam Yadav; Divya Vashishth; Kavita Sharma; Ajay Kumar; Jyoti Chahal; Sunita Dalal; Sudhir Kumar Kataria
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

5.  Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1.

Authors:  Jing Zhang; Qiu-Sha Pan; Xing-Kai Qian; Xiang-Lu Zhou; Ya-Jie Wang; Rong-Jing He; Le-Tian Wang; Yan-Ran Li; Hong Huo; Cheng-Gong Sun; Lei Sun; Li-Wei Zou; Ling Yang
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.